Latest news and press releases about Protalix BioTherapeutics, Inc. (PLX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Price
| Price | $2.68 |
| Market Cap | $216M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| P/E Ratio | 11.12 |
| Price / Book | 3.00 |
| EV / EBITDA | 7.49 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 31.61% |
| Return on Invested Capital | 23.33% |
| Return on Assets | 17.17% |
| Gross Margin | 69.20% |
| Operating Margin | 28.89% |
| Net Margin | 23.50% |
Related companies: CDXS · CHRS · GNFT · IVVD · MDWD · NTHI · OABI
Explore sector: Healthcare · Biotechnology
More sections of PLX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks